Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
V. Somogyi (Heidelberg, Germany), K. Mayer (Heidelberg, Germany), K. Kriegsmann (Heidelberg, Germany), M. Kriegsmann (Heidelberg, Germany), P. Findeisen (Heidelberg, Germany), M. Kreuter (Heidelberg, Germany). KL-6 as a potential therapeutic biomarker in fibrosing interstitial lung diseases. 820

Member's Comments

No comment yet.

Related content which might interest you: KL-6, SP-D and MMP-7 as serum biomarkers for early detection of interstitial lung diseases Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 Circulating fibrocytes as prognostic biomarkers of autoimmune interstitial lung disease Source: ERJ Open Res, 6 (4) 00481-2020; 10.1183/23120541.00481-2020 Year: 2020 Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases Source: Eur Respir J, 54 (3) 1900161; 10.1183/13993003.00161-2019 Year: 2019 Serum biomarkers as prognostic factors of autoimmune pulmonary alveolar proteinosis after whole lung lavage Source: International Congress 2016 – Orphan diseases I Year: 2016 IGFBP-2 a new interesting target in IPF Source: International Congress 2016 – ILD pathogenesis Year: 2016 Elevated alveolar antioxidant levels in chronic fibrosing interstitial lung diseases Source: Annual Congress 2008 - New therapeutic strategies in idiopathic pulmonary fibrosis Year: 2008 KL-6 is a useful serum biomarker for early detection of interstitial lung disease Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities Year: 2012 Treatment of progressive fibrosing interstitial lung diseases: a milestone in the management of interstitial lung diseases Source: Eur Respir Rev, 28 (153) 190109; 10.1183/16000617.0109-2019 Year: 2019 Serum KL-6 as a multidimensional biomarker in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Identifying serum molecular biomarkers that distinguish emphysema and early fibrotic interstitial lung disease. Source: Virtual Congress 2021 – Biomarkers and e-health in idiopathic interstitial pneumonia Year: 2021 Fibulin-1 is a novel biomarker of disease severity in pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 Biomarkers for interstitial lung disease Source: International Congress 2016 – ME1 Biomarkers for interstitial lung disease Year: 2016 Antifibrotic treatment in progressive non-IPF fibrotic interstitial lung diseases Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis Year: 2019 Serum progranulin levels in idiopathic pulmonary fibrosis and other interstitial lung diseases Source: International Congress 2018 – Idiopathic interstital pneumonias other than idiopathic pulmonary fibrosis (IPF) Year: 2018 alpha-v-beta-6 integrin may be a potential prognostic biomarker in interstitial lung disease Source: Eur Respir J 2015; 46: 486-494 Year: 2015 The analysis of prognostic factors in patients with interstitial lung diseases Source: International Congress 2015 – New insights into IIPs Year: 2015 Serum chitotriosidase levels in granulomatous lung disorders Source: Annual Congress 2006 - Clinical features and disease markers of sarcoidosis Year: 2006 Physiological study of small airway function in fibrosing interstitial lung disease Source: Eur Respir J 2007; 30: Suppl. 51, 578s Year: 2007 Current and future therapeutic approaches in idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 26: 693-703 Year: 2005